The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00379600
• Other study ID #: ARA102198
• Status: Completed
• Phase: Phase 2
• First received: September 21, 2006
• Last updated: October 24, 2016
• Start date: November 2004
• Est. completion date: December 2006

Study information

• Verified date: October 2016
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess whether the anti-inflammatory effects of rosiglitazone result in improvements in Rheumatoid Arthritis symptoms in patients for whom their existing Disease Modifying Anti-Rheumatic Drug (DMARD) treatment does not give adequate relief.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: December 2006
• Est. primary completion date: December 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Rheumatoid Arthritis insufficiently controlled by existing disease-modifying anti-rheumatic drugs

• Subjects will have at least 6 swollen joints plus 2 of the following: 6 tender joints (of 28 joints); early morning stiffness lasting more than 30 minutes; ESR greater or equal to 28mm/h

• must be receiving a stable dose of disease-modifying anti-rheumatic therapy for at least 2 months prior to participating in the study.

Exclusion criteria:

• Women who are lactating, pregnant, or planning to become pregnant during the course of the study including 30 days following conclusion of study medication

• Systolic blood pressure (SBP) >165 mmHg or diastolic blood pressure (DBP) >95 mmHg while receiving optimal antihypertensive therapy

• Any clinically significant abnormality identified on the screening physical exam, laboratory tests, or ECG, which in the judgement of the Investigator makes the subject unsuitable for inclusion in the study

• a history of alcohol abuse within the past 3 years or consumes >3 units per day for males and >2 units per day for females or has a history of cirrhosis or stigmata of chronic liver disease

• a history of liver disease or has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >2.5 times upper limit of normal and total bilirubin levels greater than 1.5 times the upper limit of normal (unless associated with predominantly indirect bilirubin or Gilbert's syndrome) at screening

• using glucocorticoid at doses >10 mg/day currently or within the last 3 months or may be expected to do so during the course of the study

• The subject's dose of NSAIDs, COX-2 inhibitors or glucocorticoids has changed at any time during the past 2 weeks prior to screening or may be expected to change during the course of the study

• The subject's dose or treatment with a statin has changed at any time during the past 3 months prior to screening or may be expected to change during the course of the study

• a history of renal disease or has serum creatinine = 132mol/L for males and =130mol for females

• has diabetes mellitus that requires medication or hyperglycaemia with a HbA1c of >7%

• History of new cardiovascular event within the last 6 months (i.e., intervention, percutaneous coronary intervention, vascular surgery, acute coronary syndrome [non Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina) or significant arrhythmia; or major intervention (e.g., cardiac surgery or angiography plus stenting) scheduled

• Concurrent or past medical history of congestive heart failure or pulmonary oedema

• A presence of severe peripheral oedema or a medically serious fluid-related event

• has significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or immunological conditions that, in the opinion of the Investigator and/or GSK medical monitor, places the subject at an unacceptable risk as a participant in this trial

• a history of malignancy in the last 5 years, except for surgically cured basal cell carcinoma (>2 years prior to first dosing)

• a history of HIV, or chronic hepatitis B or positive C serology

• a history of drug abuse

• has participated in a clinical trial within the 3 months before the start of the study for non-biological therapy; or within 6 months of a biological therapy

• on a biological therapy or has received biological therapy within 6 months prior to screening

• has donated blood in excess of 500 mL within 56 days prior to dosing

• The subject is at risk of non-compliance in following directions or adhering to study restrictions

• a history of drug or other allergy, which, in the opinion of the physician responsible, contraindicates their participation

• has anaemia defined by haemoglobin concentration <11 g/dL for males or <10 g/dL for females

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid

Intervention

Drug:
• rosiglitazone XR

Locations

Country	Name	City	State
Lithuania	GSK Investigational Site	Kaunas
Lithuania	GSK Investigational Site	Vilnius
United Kingdom	GSK Investigational Site	Glasgow	Lanarkshire
United Kingdom	GSK Investigational Site	Glasgow	Lanarkshire
United Kingdom	GSK Investigational Site	Glasgow	Lanarkshire

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Lithuania,  United Kingdom, 

References & Publications (1)

This study has not been published in the scientific literature.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Activity Score (DAS) following 6 months of treatment		6 Months
Secondary	Disease activity at 3 months and 6 months, e.g., number of affected joints Patient Assessments of Improvements in Disease Activity, e.g., fatigue and pain assessment Assessment of safety, tolerability and biological activity		Disease activity at 3 months and 6 months

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.